Seven Eight Capital, LP Axsome Therapeutics, Inc. Transaction History

Seven Eight Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$58.39 - $75.0 $529,655 - $680,325	-9,071 Reduced 70.37%	3,819 $235,000
Q4 2022 Feb 13, 2023	BUY	$39.94 - $79.72 $248,626 - $496,257	6,225 Added 93.4%	12,890 $994,000
Q3 2022 Nov 10, 2022	BUY	$36.06 - $69.85 $240,339 - $465,550	6,665 New	6,665 $297,000
Q1 2022 May 11, 2022	SELL	$23.7 - $41.39 $198,700 - $347,013	-8,384 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $577,651 - $815,861	-18,816 Reduced 69.18%	8,384 $317,000
Q3 2021 Nov 15, 2021	BUY	$19.91 - $68.26 $541,552 - $1.86 Million	27,200 New	27,200 $897,000
Q3 2019 Nov 14, 2019	SELL	$20.24 - $29.16 $178,476 - $257,132	-8,818 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$13.46 - $25.75 $118,690 - $227,063	8,818 New	8,818 $227,000

288

40.4M

365K

428K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.88B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.